|
J&J unit ends hepatitis C
drug development in crowded market
Send a link to a friend
[September 11, 2017] (Reuters)
- Janssen Sciences Ireland UC, a unit of
Johnson & Johnson, said it would discontinue further development of its
hepatitis C research, citing increased availability of a number of
effective hepatitis C therapies.
|
|
 Janssen said it would not continue the development of the
investigational hepatitis C treatment regimen JNJ-4178, a
combination of three direct acting antivirals.
The ongoing phase II studies with JNJ-4178 will be completed as
planned, with no additional development thereafter, Janssen said in
a statement on Monday.
Janssen's hepatitis research and development efforts will continue
to focus on chronic hepatitis B, the unit said.
Janssen co-developed telaprevir, a first-in-class protease inhibitor
used in combination therapy for the treatment of chronic hepatitis C
virus, a few years ago. In collaboration with Medivir AB , Janssen
later launched the second-generation protease inhibitor OLYSIO,
which is approved in several countries.
[to top of second column] |
(Reporting by Kanishka Singh in Bengaluru; Editing by Gopakumar
Warrier)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
